OS-Therapies-Logo-White

 

OS Therapies, Inc.

OS Therapies, Inc. (NYSE-A: OSTX) is a clinical-stage oncology company developing innovative cancer treatments that leverage attenuated bioengineered Listeria monocytogenes-based immunotherapies to activate the body’s natural cellular immunity defenses to fight solid tumors and prevent cancer metastases. Their lead candidate, OST-HER2, is a groundbreaking cancer immunotherapy designed to teach the immune system to identify and destroy cancer cells that produce a protein called HER2. OST-HER2 has successfully completed a Phase 2b clinical trial for the prevention of metastases to the lung in osteosarcoma patients, the most prevalent form of bone cancer.

The treatment has received rare pediatric, fast track, and orphan drug designations with the US FDA. OS Therapies is eligible to receive a priority review voucher, potentially worth $150M, if the FDA grants approval for the prevention of lung metastases in osteosarcoma patients based on the Phase 2b results. The Company is working towards achieving this milestone by the end of 2025. A planned Phase 2/3 trial using OST-HER2 to treat breast cancer and other HER2-positive tumors is scheduled for 2026.

NYSE-A: OSTX
IR Website: https://ir.ostherapies.com
NYSE Profile: https://www.nyse.com/quote/XASE:OSTX
Headquarters: Rockville, Maryland
Investor Contact: Gerald Commissiong - irpr@ostherapies.com

x-logo     linkedin-logo-white     FB-logo-white     ig-logo

TALK TO MANAGEMENT

OS Therapies is always available to talk to current and potential investors. They're happy to answer any questions you may have and tell you what makes their story unique. Please fill out this form, and we will connect you shortly.

Press Releases & Media Coverage

Social Media Updates

Investor Presentation

Stock Chart (Intraday)

Stock Chart (Historical)

Stock Detail

Lead Drug Candidate: Crofelemer

How Crofelemer Works

Jaguar/Napo Product Portfolio – Crofelemer Pipeline

Videos – Jaguar Health: Improving Lives

Global Market Growth Opportunities

2023 Critical Activities to Unlock Jaguar Health's Value Potential

Commercial Rights and Partnerships

Jaguar and Magdalena Biosciences Collaboration

Financial Summary

Analyst Coverage

A Deep and Seasoned Leadership Team

SEC Filings

Financials

Risks & Disclosures

OS-Therapies-Logo-White

The OS Therapies management and investor relations team are available to talk to current and potential investors. They're happy to answer your questions and tell you what makes their story unique. Please fill out this form, and we will connect you shortly.

• Directly hear the OS Therapies story
• Ask your questions
• Submit the form below, and someone will get in touch with you as soon as possible

Note: Company management or its representative can only discuss and disclose information that is already available in the public domain. They will do their best to clarify such information to the extent permitted by securities law and industry regulations.